TY - JOUR
T1 - Later onset focal epilepsy with roots in childhood
T2 - Evidence from early learning difficulty and brain volumes in the Human Epilepsy Project
AU - Pellinen, Jacob
AU - Pardoe, Heath
AU - Sillau, Stefan
AU - Barnard, Sarah
AU - French, Jacqueline
AU - Knowlton, Robert
AU - Lowenstein, Daniel
AU - Cascino, Gregory D.
AU - Glynn, Simon
AU - Jackson, Graeme
AU - Szaflarski, Jerzy
AU - Morrison, Chris
AU - Meador, Kimford J.
AU - Kuzniecky, Ruben
AU - on behalf of the Human Epilepsy Project Investigators
N1 - Funding Information:
J.P. has received research support from the Department of Neurology at the University of Colorado School of Medicine, the Colorado Clinical and Translational Sciences Institute, NIH/NINDS, and the American Epilepsy Society. J.P. serves as chair of the professional advisory board for the Epilepsy Foundation of Colorado and Wyoming (unpaid), serves as the Epilepsy section editor for and , and has received salary support for advisory board work for SK Life Science. J.F. receives salary support from the Epilepsy Foundation and for consulting work and/or attending scientific advisory boards on behalf of the Epilepsy Study Consortium for Aeonian/Aeovian, Alterity Therapeutics, Anavex, Arkin Holdings, Angelini Pharma, Arvelle Therapeutics, Athenen Therapeutics/Carnot Pharma, Autifony Therapeutics, Baergic Bio, Biogen, Biohaven Pharmaceuticals, BioMarin Pharmaceutical, BioXcel Therapeutics, Bloom Science, BridgeBio Pharma, Camp4 Therapeutics Corporation, Cerebral Therapeutics, Cerevel, Clinical Education Alliance, Coda Biotherapeutics, Corlieve Therapeutics, Crossject, Eisai, Eliem Therapeutics, Encoded Therapeutics, Engage Therapeutics, Engrail, Epalex, Epihunter, Epiminder, Epitel, Equilibre BioPharmaceuticals, Greenwich Biosciences, Grin Therapeutics, GW Pharma, Janssen Pharmaceutica, Jazz Pharmaceuticals, Knopp Biosciences, Lipocine, LivaNova, Longboard Pharmaceuticals, Lundbeck, Marinus, Mend Neuroscience, Merck, NeuCyte, Neumirna Therapeutics, Neurocrine, Neuroelectrics USA Corporation, Neuronetics, Neuropace, NxGen Medicine, Ono Pharmaceutical Co., Otsuka Pharmaceutical Development, Ovid Therapeutics, Paladin Labs, Passage Bio, Pfizer, Praxis, PureTech LTY, Rafa Laboratories, SK Life Sciences, Sofinnova, Stoke, Supernus, Synergia Medical, Takeda, UCB, Ventus Therapeutics, Xenon, Xeris, Zogenix, and Zynerba. J.F. has also received research support from the Epilepsy Study Consortium (funded by Andrews Foundation, Eisai, Engage, Lundbeck, Pfizer, SK Life Science, Sunovion, UCB, and Vogelstein Foundation), Epilepsy Study Consortium/Epilepsy Foundation (funded by UCB), GW/FACES, and NINDS. J.F. is on the editorial board of and . J.F. is Chief Medical/Innovation Officer for the Epilepsy Foundation. J.F. has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Angelini Pharma, Clinical Education Alliance, NeuCyte, Neurocrine, Praxis, and Xenon. K.J.M. has received research support from the National Institutes of Health, Eisai, and Medtronic; the Epilepsy Study Consortium pays K.J.M.'s university for his research consultant time related in the past to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher‐Smith Laboratories, and UCB Pharma. The remaining authors have no conflicts of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Current Neurology Neuroscience Reports Lancet Neurology Neurology Today
Funding Information:
We thank the HEP1 participants for making this study possible. Detailed information about HEP1 can be found at http://www.humanepilepsyproject.org . There was no targeted funding for this study. Creation of HEP was sponsored by the Epilepsy Study Consortium. Funding for HEP was received from industry, philanthropy, and foundations (UCB Pharma, Eisai, Pfizer, Lundbeck, Sunovion, Andrews Foundation, Vogelstein Foundation, Finding a Cure for Epilepsy and Seizures [FACES], and Friends of FACES). The funders of HEP had no role in the design or conduct of this study, the collection, management, analysis, or interpretation of the data, the preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.
Publisher Copyright:
© 2023 International League Against Epilepsy.
PY - 2023/10
Y1 - 2023/10
N2 - Objective: Visual assessment of magnetic resonance imaging (MRI) from the Human Epilepsy Project 1 (HEP1) found 18% of participants had atrophic brain changes relative to age without known etiology. Here, we identify the underlying factors related to brain volume differences in people with focal epilepsy enrolled in HEP1. Methods: Enrollment data for participants with complete records and brain MRIs were analyzed, including 391 participants aged 12–60 years. HEP1 excluded developmental or cognitive delay with intelligence quotient <70, and participants reported any formal learning disability diagnoses, repeated grades, and remediation. Prediagnostic seizures were quantified by semiology, frequency, and duration. T1-weighted brain MRIs were analyzed using Sequence Adaptive Multimodal Segmentation (FreeSurfer v7.2), from which a brain tissue volume to intracranial volume ratio was derived and compared to clinically relevant participant characteristics. Results: Brain tissue volume changes observable on visual analyses were quantified, and a brain tissue volume to intracranial volume ratio was derived to compare with clinically relevant variables. Learning difficulties were associated with decreased brain tissue volume to intracranial volume, with a ratio reduction of.005 for each learning difficulty reported (95% confidence interval [CI] = −.007 to −.002, p =.0003). Each 10-year increase in age at MRI was associated with a ratio reduction of.006 (95% CI = −.007 to −.005, p <.0001). For male participants, the ratio was.011 less than for female participants (95% CI = −.014 to −.007, p <.0001). There were no effects from seizures, employment, education, seizure semiology, or temporal lobe electroencephalographic abnormalities. Significance: This study shows lower brain tissue volume to intracranial volume in people with newly treated focal epilepsy and learning difficulties, suggesting developmental factors are an important marker of brain pathology related to neuroanatomical changes in focal epilepsy. Like the general population, there were also independent associations between brain volume, age, and sex in the study population.
AB - Objective: Visual assessment of magnetic resonance imaging (MRI) from the Human Epilepsy Project 1 (HEP1) found 18% of participants had atrophic brain changes relative to age without known etiology. Here, we identify the underlying factors related to brain volume differences in people with focal epilepsy enrolled in HEP1. Methods: Enrollment data for participants with complete records and brain MRIs were analyzed, including 391 participants aged 12–60 years. HEP1 excluded developmental or cognitive delay with intelligence quotient <70, and participants reported any formal learning disability diagnoses, repeated grades, and remediation. Prediagnostic seizures were quantified by semiology, frequency, and duration. T1-weighted brain MRIs were analyzed using Sequence Adaptive Multimodal Segmentation (FreeSurfer v7.2), from which a brain tissue volume to intracranial volume ratio was derived and compared to clinically relevant participant characteristics. Results: Brain tissue volume changes observable on visual analyses were quantified, and a brain tissue volume to intracranial volume ratio was derived to compare with clinically relevant variables. Learning difficulties were associated with decreased brain tissue volume to intracranial volume, with a ratio reduction of.005 for each learning difficulty reported (95% confidence interval [CI] = −.007 to −.002, p =.0003). Each 10-year increase in age at MRI was associated with a ratio reduction of.006 (95% CI = −.007 to −.005, p <.0001). For male participants, the ratio was.011 less than for female participants (95% CI = −.014 to −.007, p <.0001). There were no effects from seizures, employment, education, seizure semiology, or temporal lobe electroencephalographic abnormalities. Significance: This study shows lower brain tissue volume to intracranial volume in people with newly treated focal epilepsy and learning difficulties, suggesting developmental factors are an important marker of brain pathology related to neuroanatomical changes in focal epilepsy. Like the general population, there were also independent associations between brain volume, age, and sex in the study population.
KW - clinical neurology
KW - cognition
KW - development
KW - magnetic resonance imaging
KW - seizures
UR - http://www.scopus.com/inward/record.url?scp=85167334707&partnerID=8YFLogxK
U2 - 10.1111/epi.17727
DO - 10.1111/epi.17727
M3 - Article
C2 - 37517050
AN - SCOPUS:85167334707
SN - 0013-9580
VL - 64
SP - 2761
EP - 2770
JO - Epilepsia
JF - Epilepsia
IS - 10
ER -